Literature DB >> 3149144

Long-term oral anticoagulant therapy in elderly patients.

L S Wickramasinghe1, S K Basu, S K Bansal.   

Abstract

Forty-nine patients aged 65-89 years, treated for 6 months-6 years (mean 3.9 years) over a total of 195 patient years, were studied. The efficacy of anticoagulant control or the occurrence of complications or treatment failures did not vary with the age, sex, social status, mobility, visual acuity, domiciliary supervision of medication or the indication for anticoagulation. A significant correlation was observed between the concomitant drug therapy and anticoagulant control (P less than 0.001) but not with the occurrence of complications and treatment failures. Poor anticoagulant control was observed particularly in those receiving drugs known to potentiate warfarin effect and in whom more changes were made to their concomitant drug therapy. Five patients who experienced six non-fatal haemorrhages (two major and four minor) showed poor overall anticoagulant control from the outset (P less than 0.01). The treatment failure rate was 4%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149144     DOI: 10.1093/ageing/17.6.388

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  16 in total

Review 1.  Out-of-hospital coagulation monitoring and management.

Authors:  J E Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

3.  Safety of anticoagulation in the elderly: reasons for discontinuing therapy.

Authors:  P A O'Neill; D Crossley; D A Taberner; D S Fairweather
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.

Authors:  Russell A Wilke; Richard L Berg; Humberto J Vidaillet; Michael D Caldwell; James K Burmester; Michael A Hillman
Journal:  Clin Med Res       Date:  2005-11

6.  Anticoagulant drugs in the elderly.

Authors:  L S Wickramasinghe; S K Basu; S K Bansal
Journal:  BMJ       Date:  1989-02-18

7.  Stroke prevention.

Authors:  R Tozer; I R Hastie
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

8.  Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic.

Authors:  J P Pell; B McIver; P Stuart; D N Malone; J Alcock
Journal:  Br J Gen Pract       Date:  1993-04       Impact factor: 5.386

Review 9.  Treatment of stroke in older patients. A state of the art review.

Authors:  G Harper
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 10.  Adverse drug reactions. An overview of special considerations in the management of the elderly patient.

Authors:  L A Brawn; C M Castleden
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.